Virtual Library
Start Your Search
Kirstin Perdrizet
Author of
-
+
P1.01 - Advanced NSCLC (ID 158)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.01-30 - Non-Small Cell Lung Cancer (NSCLC) Next Generation Sequencing (NGS): Integrating Genomic Sequencing into a Publicly Funded Health Care Model (Now Available) (ID 2588)
09:45 - 18:00 | Author(s): Kirstin Perdrizet
- Abstract
Background
Standard of care (SOC) molecular diagnostics for stage IV NSCLC patients in Ontario, Canada includes publicly reimbursed EGFR/ALK, and BRAF/ ROS-1 testing in selected cases. Other genomic alterations are not tested routinely at all institutions; however, enhanced molecular testing may broaden treatment options for patients by identifying actionable targets. This study evaluated costs, identified actionable targets, and determined clinical trial eligibility as a result of using the Oncomine Comprehensive Assay v3 (OCA v3, ThermoFisher) NGS in stage IV NSCLC patients at a single institution.
Method
This prospective study of stage IV NSCLC out-patients at Princess Margaret Cancer Centre (Toronto) began in February 2018 and recruitment is ongoing (NCT03558165). NSCLC patients without EGFR/ALK/KRAS/BRAF alteration (unless failure of prior targeted therapy and tissue rebiopsy), had diagnostic samples tested by OCAv3 (ThermoFisher; 161 genes: hotspots, fusions, and copy number variations). Primary endpoints were identification of incremental actionable targets and clinical trial opportunities as a result of broader OCAv3 testing. Secondary endpoints include feasibility and cost from the Canadian public healthcare perspective.
Result
From Feb 2018- Jan 2019 65 patients were enrolled [62% (N=40) completed/ 21% (N=14) screen fail/ 17% (N=11) pending], median age of completed cohort was 65, 60% (N=24) female, never/light smokers 68% (N=27), Asian 38% (N=15), previously treated 33% (N=13). Actionable targets beyond SOC were identified in 33% (N=13): ERBB2 (N=8), BRAFV600 (N=3), NRG fusion (N=1), MET exon 14 (N=1). Failure of NGS was secondary to insufficient tissue. 91% (N=10) of screen failures was secondary to tissue exhaustion from prior sequential SOC molecular testing. New clinical trial options were identified in 70% as a result of OCA v3 testing. Incremental costs per case beyond EGFR/ALK are estimated at $540 CAD. If ROS-1 and BRAF testing were publicly reimbursed at current rates, the incremental profiling cost with OCAv3 would be $90 CAD per case.
Conclusion
The OCAv3 consolidates genomic testing, identifies additional actionable targets, and substantially increases clinical trial eligibility for patients at a small incremental cost. Sample failures are reflective of exhausted diagnostic tissue as a result of prior sequential genomic testing. The key barrier to implementation of NGS remains funding in the Canadian health care system.
-
+
P2.03 - Biology (ID 162)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Biology
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.03-11 - Impact of Ethnicity on Outcome in Never Smokers with EGFR and ALK Wildtype (EGFR/ALK-Wildtype) Lung Adenocarcinomas (ID 2035)
10:15 - 18:15 | Author(s): Kirstin Perdrizet
- Abstract
Background
EGFR-mutations and ALK-rearrangements are frequent in lung adenocarcinoma (LUAD) samples from never smoker patients. Nevertheless, up to a quarter of all LUAD cases in never smokers are EGFR/ALK-wildtype: these patients have limited therapeutic options and few well-established clinical and molecular predictors of outcome. Our main objectives here were to investigate the prognostic impact of ethnicity in never smoker patients with EGFR/ALK-wildtype LUAD and seek for specific somatic events correlated to ethnical background in these patients.
Method
We included 85 samples from lifetime never-smoker patients with EGFR/ALK-wildtype LUAD collected from surgical resection with curative intent. Stages 1/2/3 were identified in 56 (66%)/15 (18%)/14 (16%) samples. A subset of those samples (n=46), with similar stage distribution, had snap-frozen tumor and paired-adjacent tissue available and were submitted to paired-end whole-exome sequencing. Fisher’s exact and Chi-squared tests were used to compare specific mutations between Asians vs non-Asians. Recurrence-free-survival (RFS) was calculated based on the Kaplan-Meier method; Cox modeling was used to generate hazard ratios (HR), adjusted for key clinical features.
Result
Most patients in the cohort were female (63/85, 74%); the median age was 68 years; median follow-up was 51 months. According to self-reports, 19/85 (22%) and 66/85 (78%) patients identified as Asians and non-Asians, respectively; no major clinical and pathologic differences were identified between these populations. Five-year recurrence free survival was significantly lower for Asians compared to non-Asians (50% vs. 78%, adjusted HR = 2.9; CI = 1.1-7.8, p=0.02), Figure 1. Among somatic events, in-frame deletions in CNPY3 (Toll-like receptor-specific co-chaperone for HSP90B1) were more frequent in Asians (30%) compared to non-Asians (18%). In contrast, DDX11 missense mutations (21% vs 0%; nucleic acid binding protein involved in genome stability), NOTCH2 multi-hits and frame-shift deletions (7% vs 1%), and KRAS missense mutations (7% vs 0%) were more frequently altered in non-Asians than in Asians.
Conclusion
In our cohort of never-smoker patients with EGFR/ALK-wildtype LUAD, Asian patients showed higher relapse rates than non-Asians. We identified differentially mutated genes by ethnicity that may partly account for these differences in outcome. (SNMF and AFF contributed equally)